SH PHARMA (02607) Halts Clinical Trial and Further Development of Salvianolic Acid A for Injection

Stock News07-24

SH PHARMA (02607) has announced its decision to terminate the clinical trial and subsequent development of Salvianolic Acid A for Injection. This move is aimed at optimizing the allocation of research and development resources and concentrating on more advantageous projects.

The decision was made after a comprehensive evaluation of factors including the drug's future market value, business synergies, and the costs of further development. Salvianolic Acid A for Injection is a Class 1.2 innovative traditional Chinese medicine, intended for the treatment of coronary heart disease and angina pectoris.

In June 2016, the project received approval from the National Medical Products Administration to commence clinical trials. It is currently in the Phase II clinical trial stage. To date, the total cumulative investment in this project amounts to approximately RMB 37.43 million. The company has decided to cease the clinical trial and further development of this project to better allocate its R&D resources.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1173725205?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-24 19:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173725205","market":"us","top_or_hot":-1,"title":"SH PHARMA (02607) Halts Clinical Trial and Further Development of Salvianolic Acid A for Injection","media":"Stock News","content":"<p><b>SH PHARMA (02607)</b> has announced its decision to terminate the clinical trial and subsequent development of Salvianolic Acid A for Injection. This move is aimed at optimizing the allocation of research and development resources and concentrating on more advantageous projects.<br><br>The decision was made after a comprehensive evaluation of factors including the drug's future market value, business synergies, and the costs of further development. Salvianolic Acid A for Injection is a Class 1.2 innovative traditional Chinese medicine, intended for the treatment of coronary heart disease and angina pectoris.<br><br>In June 2016, the project received approval from the National Medical Products Administration to commence clinical trials. It is currently in the Phase II clinical trial stage. To date, the total cumulative investment in this project amounts to approximately RMB 37.43 million. The company has decided to cease the clinical trial and further development of this project to better allocate its R&D resources.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SH PHARMA (02607) Halts Clinical Trial and Further Development of Salvianolic Acid A for Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSH PHARMA (02607) Halts Clinical Trial and Further Development of Salvianolic Acid A for Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-24 19:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>SH PHARMA (02607)</b> has announced its decision to terminate the clinical trial and subsequent development of Salvianolic Acid A for Injection. This move is aimed at optimizing the allocation of research and development resources and concentrating on more advantageous projects.<br><br>The decision was made after a comprehensive evaluation of factors including the drug's future market value, business synergies, and the costs of further development. Salvianolic Acid A for Injection is a Class 1.2 innovative traditional Chinese medicine, intended for the treatment of coronary heart disease and angina pectoris.<br><br>In June 2016, the project received approval from the National Medical Products Administration to commence clinical trials. It is currently in the Phase II clinical trial stage. To date, the total cumulative investment in this project amounts to approximately RMB 37.43 million. The company has decided to cease the clinical trial and further development of this project to better allocate its R&D resources.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0020","symbol_name":"浦东新区","start_time":0,"source_url":"","article_id":"1173725205","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173725205","pubTimestamp":1784893699,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SH PHARMA (02607) has announced its decision to terminate the clinical trial and subsequent development of Salvianolic Acid A for Injection. This move is aimed at optimizing the allocation of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","BK0020":"浦东新区","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","BK1197":"保健护理产品经销商","BK0184":"上海国资改革","BK0183":"MSCI概念","BK0188":"融资融券","BK0012":"证金概念","BK0187":"一线龙头","BK0028":"国家队","MDTX":"Corgi MediaTek 2x Daily ETF","BK0175":"白马股","PSYK":"PSYK ETF","BK0099":"上海本地重组","02607":"上海医药","BMED":"iShares Health Innovation Active ETF","BK0209":"零售","IBBQ":"Invesco Nasdaq Biotechnology ETF","BK0196":"行业龙头","BK0097":"医药电商"},"translate_title":"上海医药(02607)暂停注射用丹酚酸A临床试验及进一步开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":1,"02607":1,"IBBJ":1,"BMED":1,"PSYK":1,"MDTX":1,"IBBQ":1},"content_text":"SH PHARMA (02607) has announced its decision to terminate the clinical trial and subsequent development of Salvianolic Acid A for Injection. This move is aimed at optimizing the allocation of research and development resources and concentrating on more advantageous projects.The decision was made after a comprehensive evaluation of factors including the drug's future market value, business synergies, and the costs of further development. Salvianolic Acid A for Injection is a Class 1.2 innovative traditional Chinese medicine, intended for the treatment of coronary heart disease and angina pectoris.In June 2016, the project received approval from the National Medical Products Administration to commence clinical trials. It is currently in the Phase II clinical trial stage. To date, the total cumulative investment in this project amounts to approximately RMB 37.43 million. The company has decided to cease the clinical trial and further development of this project to better allocate its R&D resources.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1173725205","isCrawlerRequest":true}